Gonadal development and function after immature testicular tissue banking as part of high-risk gonadotoxic treatment.
follow-up study
gonadal function
male fertility preservation
testicular biopsy
testicular growth
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
29
03
2023
received:
01
04
2022
accepted:
30
03
2023
medline:
26
6
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
ppublish
Résumé
Experimental fertility preservation programs have been started to safeguard the future fertility of prepubertal and pubertal males requiring high-risk gonadotoxic treatment protocols. However, long-term follow-up studies evaluating the effects on their gonadal development and function related to the testicular biopsy procedure are rather limited. This two-center follow-up study (between 2002 and 2020) evaluated the gonadal development and function of a cohort of 59 prepubertal and pubertal males who have been offered immature testicular tissue banking (TTB) prior to conventional high-risk chemo- and/or radiotherapy (HR-C/R) or conditioning therapy before hematopoietic stem cell transplantation (CT-HSCT). The aim is to investigate the long-term impact of the testicular biopsy procedure and the high-risk gonadotoxic treatment. Testicular growth and the reproductive hormones luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), and inhibin B (INHB) were analyzed after treatment completion, and compared between males accepting TTB and those refusing TTB (control) as well as between HR-C/R and CT-HSCT treatment protocols. Of the 59 prepubertal and pubertal males included, 25 were treated by HR-C/R and 34 required CT-HSCT. TTB was accepted for 39 males and refused for 20 males. Most patients were prepubertal at diagnosis (85%), at TTB (79%), and at treatment completion (76%), and pubertal or postpubertal at their last follow-up visit (66%). After 5.0 (1.0-13.0) years post treatment, most patients show normal testicular volumes (83%) and normal LH (89%), FSH (87%), T (87%), and INHB (79%) serum levels. The testicular biopsy procedure did not have an effect on testicular growth, LH, FSH, T, and INHB. Significantly more small postpubertal testicular volumes (p = .0278) and low INHB serum levels (p = .0130) were recorded after CT-HSCT, especially after myeloablative conditioning. The clinical follow-up data demonstrate no effect related to the biopsy procedure, but a substantial risk for impaired gonadal development after high-risk gonadotoxic treatment, in particular myeloablative CT-HSCT. Longer follow-up studies with a larger study population are needed to confirm these preliminary findings.
Sections du résumé
BACKGROUND
BACKGROUND
Experimental fertility preservation programs have been started to safeguard the future fertility of prepubertal and pubertal males requiring high-risk gonadotoxic treatment protocols. However, long-term follow-up studies evaluating the effects on their gonadal development and function related to the testicular biopsy procedure are rather limited.
DESIGN
METHODS
This two-center follow-up study (between 2002 and 2020) evaluated the gonadal development and function of a cohort of 59 prepubertal and pubertal males who have been offered immature testicular tissue banking (TTB) prior to conventional high-risk chemo- and/or radiotherapy (HR-C/R) or conditioning therapy before hematopoietic stem cell transplantation (CT-HSCT). The aim is to investigate the long-term impact of the testicular biopsy procedure and the high-risk gonadotoxic treatment. Testicular growth and the reproductive hormones luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), and inhibin B (INHB) were analyzed after treatment completion, and compared between males accepting TTB and those refusing TTB (control) as well as between HR-C/R and CT-HSCT treatment protocols.
RESULTS
RESULTS
Of the 59 prepubertal and pubertal males included, 25 were treated by HR-C/R and 34 required CT-HSCT. TTB was accepted for 39 males and refused for 20 males. Most patients were prepubertal at diagnosis (85%), at TTB (79%), and at treatment completion (76%), and pubertal or postpubertal at their last follow-up visit (66%). After 5.0 (1.0-13.0) years post treatment, most patients show normal testicular volumes (83%) and normal LH (89%), FSH (87%), T (87%), and INHB (79%) serum levels. The testicular biopsy procedure did not have an effect on testicular growth, LH, FSH, T, and INHB. Significantly more small postpubertal testicular volumes (p = .0278) and low INHB serum levels (p = .0130) were recorded after CT-HSCT, especially after myeloablative conditioning.
CONCLUSION
CONCLUSIONS
The clinical follow-up data demonstrate no effect related to the biopsy procedure, but a substantial risk for impaired gonadal development after high-risk gonadotoxic treatment, in particular myeloablative CT-HSCT. Longer follow-up studies with a larger study population are needed to confirm these preliminary findings.
Substances chimiques
Luteinizing Hormone
9002-67-9
Follicle Stimulating Hormone
9002-68-0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30370Subventions
Organisme : Research Program of the Research Foundation-Flanders
Organisme : Kom op tegen Kanker (Stand up to Cancer-Flemish Cancer Society)
Organisme : Wetenschappelijk Fonds Willy Gepts of Universitair Ziekenhuis Brussel
Informations de copyright
© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Winther JF, Kenborg L, Byrne J, et al. Childhood cancer survivor cohorts in Europe. Acta Oncol (Madr). 2015;54(5):655-668. 10.3109/0284186X.2015.1008648
Allen CM, Lopes F, Mitchell RT, Spears N. How does chemotherapy treatment damage the prepubertal testis? Reproduction. 2018;156(6):R209-R233. 10.1530/REP-18-0221
Tonorezos ES, Hudson MM, Edgar AB, et al. Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer. Lancet Diabetes Endocrinol. 2015;3(7):545-555. 10.1016/S2213-8587(15)00038-8
Oosterhuis BE, Goodwin T, Kiernan M, Hudson MM, Dahl GV. Concerns about infertility risks among pediatric oncology patients and their parents. Pediatr Blood Cancer. 2008;50(1):85-89. 10.1002/pbc.21261
Tonsing KN, Ow R. Quality of life, self-esteem, and future expectations of adolescent and young adult cancer survivors. Health Soc Work. 2018;43(1):15-21. 10.1093/hsw/hlx047
Hammond C, Abrams JR, Syrjala KL. Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls. J Clin Oncol. 2007;25(23):3511-3517. 10.1200/JCO.2007.10.8993
Mosher CE, DuHamel KN, Rini C, Corner G, Lam J, Redd WH. Quality of life concerns and depression among hematopoietic stem cell transplant survivors. Support Care Cancer. 2011;19(9):1357-1365. 10.1007/s00520-010-0958-y
Braye A, Tournaye H, Goossens E. Setting up a cryopreservation programme for immature testicular tissue: lessons learned after more than 15 years of experience. Clin Med Insights Reprod Health. 2019;13:117955811988634. 10.1177/1179558119886342
Picton HM, Wyns C, Anderson RA, et al. A European perspective on testicular tissue cryopreservation for fertility preservation in prepubertal and adolescent boys. Hum Reprod. 2015;30(11):2463-2475. 10.1093/humrep/dev190
Pietzak EJ, Tasian GE, Tasian SK, et al. Histology of testicular biopsies obtained for experimental fertility preservation protocol in boys with cancer. J Urol. 2015;194(5):1420-1424. 10.1016/j.juro.2015.04.117
Sadri-Ardekani H, McLean TW, Kogan S, et al. Experimental testicular tissue banking to generate spermatogenesis in the future: a multidisciplinary team approach. Methods. 2016;99:120-127. 10.1016/j.ymeth.2016.02.013
Ho WLC, Bourne H, Gook D, et al. A short report on current fertility preservation strategies for boys. Clin Endocrinol (Oxf). 2017;87(3):279-285. 10.1111/cen.13377
Smith BM, Duncan FE, Ataman L, et al. The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond. Future Oncol. 2018;14(29):3059-3072. 10.2217/fon-2018-0278
Ming JM, Chua ME, Lopes RI, Maloney AM, Gupta AA, Lorenzo AJ. Cryopreservation of testicular tissue in pre-pubertal and adolescent boys at risk for infertility: a low risk procedure. J Pediatr Urol. 2018;14(3):274.e1-274.e5. 10.1016/j.jpurol.2018.02.016
Valli-Pulaski H, Peters KA, Gassei K, et al. Testicular tissue cryopreservation: 8 years of experience from a coordinated network of academic centers. Hum Reprod. 2019;34(6):966-977. 10.1093/humrep/dez043
Goossens E, Jahnukainen K, Mitchell R, et al. Fertility preservation in boys: recent developments and new insights. Hum Reprod Open. 2020;2020(3):hoaa016. 10.1093/hropen/hoaa016
Ginsberg JP, Carlson CA, Lin K, et al. An experimental protocol for fertility preservation in prepubertal boys recently diagnosed with cancer: a report of acceptability and safety. Hum Reprod. 2010;25(1):37-41. 10.1093/humrep/dep371
Ginsberg JP, Li Y, Carlson CA, et al. Testicular tissue cryopreservation in prepubertal male children: an analysis of parental decision-making. Pediatr Blood Cancer. 2014;61(9):1673-1678. 10.1002/PBC.25078
van den Berg H, Repping S, van der Veen F. Parental desire and acceptability of spermatogonial stem cell cryopreservation in boys with cancer. Hum Reprod. 2007;22(2):594-597. 10.1093/humrep/del375
Gupta AA, Donen RM, Sung L, et al. Testicular biopsy for fertility preservation in prepubertal boys with cancer: identifying preferences for procedure and reactions to disclosure practices. J Urol. 2016;196(1):219-224. 10.1016/j.juro.2016.02.2967
Mathiesen S, Sørensen K, Nielsen MM, et al. Male gonadal function after allogeneic hematopoietic stem cell transplantation in childhood: a cross-sectional, population-based study. Biol Blood Marrow Transplant. 2020;26(9):1635-1645. 10.1016/j.bbmt.2020.05.009
Borgström B, Fridström M, Gustafsson B, Ljungman P, Rodriguez-Wallberg KA. A prospective study on the long-term outcome of prepubertal and pubertal boys undergoing testicular biopsy for fertility preservation prior to hematologic stem cell transplantation. Pediatr Blood Cancer. 2020;67(9):e28507. 10.1002/pbc.28507
Mathiesen S, Sørensen K, Ifversen M, et al. Childhood reproductive hormone levels after pediatric hematopoietic stem cell transplantation in relation to adult testicular function. Endocr Connect. 2021;10(10):1352-1365. 10.1530/EC-21-0154
Kanbar M, de Michele F, Giudice MG, Desmet L, Poels J, Wyns C. Long-term follow-up of boys who have undergone a testicular biopsy for fertility preservation. Hum Reprod. 2021;36(1):26-39. 10.1093/humrep/deaa281
Uijldert M, Meißner A, de Melker AA, et al. Development of the testis in pre-pubertal boys with cancer after biopsy for fertility preservation. Hum Reprod. 2017;32(12):2366-2372. 10.1093/humrep/dex306
Wyns C, Curaba M, Petit S, et al. Management of fertility preservation in prepubertal patients: 5 years’ experience at the Catholic University of Louvain. Hum Reprod. 2011;26(4):737-747. 10.1093/humrep/deq387
Medrano JV, del Andrés M M, García S, et al. Basic and clinical approaches for fertility preservation and restoration in cancer patients. Trends Biotechnol. 2018;36(2):199-215. 10.1016/j.tibtech.2017.10.010
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13-23. 10.1136/adc.45.239.13
Braye A, Böhler S, Vloeberghs V, et al. Testicular biopsy for fertility preservation in early-diagnosed Klinefelter patients: patient characteristics and long-term follow-up. Reprod Biomed Online. 2022;44(5):889-895. 10.1016/j.rbmo.2022.01.014
Rombaut C, Faes K, Goossens E. The effect of a unilateral orchiectomy before gonadotoxic treatment on the contralateral testis in adult and prepubertal rats. PLoS One. 2016;11(10):e0164922. 10.1371/journal.pone.0164922
van Casteren NJ, van der Linden GHM, Hakvoort-Cammel FGAJ, Hählen K, Dohle GR, van den Heuvel-Eibrink MM. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer. 2009;52(1):108-112. 10.1002/pbc.21780
Kelsey TW, McConville L, Edgar AB. Follicle stimulating hormone is an accurate predictor of azoospermia in childhood cancer survivors. PLoS One. 2017;12(7):e0181377. 10.1371/journal.pone.0181377
Soliman AT, Alaaraj N, Yassin M. The effects of treatment with blood transfusion, iron chelation and hydroxyurea on puberty, growth and spermatogenesis in sickle cell disease (SCD): a short update. Acta Biomed. 2021;92(4):e2021386. 10.23750/abm.v92i4.11917
Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93(7):988-993. 10.3324/haematol.11515
Vuong C, Van Uum SHM, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31(1):98-132. 10.1210/er.2009-0009
DeBaun MR. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review. Expert Rev Hematol. 2014;7(6):767-773. 10.1586/17474086.2014.959922
Rostami T, Mohammadifard MA, Ansari S, et al. Indicators of male fertility potential in adult patients with beta-thalassemia major: a comparative study between patients undergone allogeneic stem cell transplantation and transfusion-dependent patients. Fertil Res Pract. 2020;6:4. 10.1186/s40738-020-00071-6
Yacobovich J, Tamary H. Thalassemia major and sickle cell disease in adolescents and young adults. Acta Haematol. 2014;132(3-4):340-347. 10.1159/000360235
Carlsen E, Andersen AG, Buchreitz L, et al. Inter-observer variation in the results of the clinical andrological examination including estimation of testicular size. Int J Androl. 2000;23(4):248-253. 10.1046/j.1365-2605.2000.00240.x